Weight loss and cholesterol lowering in the elderly. by Rolland, Catherine & Broom, Iain
 
 
 
 
OpenAIR@RGU 
 
The Open Access Institutional Repository 
at Robert Gordon University 
 
http://openair.rgu.ac.uk 
 
This is an author produced version of a paper published in  
 
Geriatric Medicine: GM2 ; Heart and Diabetes (ISSN 0268-201X) 
 
This version may not include final proof corrections and does not include 
published layout or pagination. 
 
 
Citation Details 
 
Citation for the version of the work held in ‘OpenAIR@RGU’: 
 
ROLLAND, C. and BROOM, I., 2010. Weight loss and cholesterol 
lowering in the elderly. Available from OpenAIR@RGU. [online]. 
Available from: http://openair.rgu.ac.uk 
 
 
Citation for the publisher’s version: 
 
ROLLAND, C. and BROOM, I., 2010. Weight loss and cholesterol 
lowering in the elderly. Geriatric Medicine: GM2 ; Heart and 
Diabetes, 40 (Supp. 4), pp. 27-36. 
 
 
Copyright 
Items in ‘OpenAIR@RGU’, Robert Gordon University Open Access Institutional Repository, 
are protected by copyright and intellectual property law. If you believe that any material 
held in ‘OpenAIR@RGU’ infringes copyright, please contact openair-help@rgu.ac.uk with 
details. The item will be removed from the repository while the claim is investigated. 
Weight loss and cholesterol lowering in the elderly 
 
Weight loss and cholesterol lowering in the elderly remains a controversial issue. 
Obesity is considered to be problematic as a result of associated dyslipidemia, 
cardiovascular disease and mortality. Diet, exercise, medication and laparoscopic 
gastric banding all demonstrate important potential for achieving safe weight loss and 
cholesterol lowering in the elderly. This evidence, however, remains minimal and a 
case specific approach is recommended until more robust guidelines can be 
developed. 
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Key points: 
- Weight loss and cholesterol lowering in the elderly remains a controversial 
issue. 
- Weight loss achieved by diet and exercise results in improvements in 
triacylglycerols and total cholesterol. 
- Statin therapy appears to be a safe approach for cholesterol lowering in the 
elderly. 
- More research in the use of Xenical for weight loss and potential cholesterol 
lowering in the elderly is required. 
- Laparoscopic gastric banding may be an important option for weight loss and 
improvement in dyslipidemia in the elderly. 
- There is a need for more research in the effects of weight loss and cholesterol 
lowering in the elderly. 
 
Introduction 
 
As the obesity rates increase along with our aging population, we are encountering 
more cases of elderly obese individuals (1). The subject of weight loss in the elderly 
has been a controversial issue for a number of years, as it is often associated with 
increased mortality rates (2). There are caveats, however, as this is shadowed by 
voluntary versus involuntary weight loss, where involuntary weight loss has been 
shown to result from concomitant diseases such as cancer, renal disease, heart 
failure and chronic obstructive pulmonary disease. Some evidence has demonstrated 
that individualised voluntary weight loss can have beneficial effects in terms of 
mortality, cardiovascular disease, arthritis, osteoporosis and quality of life. Obesity is 
considered to be problematic in the elderly as a result of associated dyslipidemia with 
concomitant development of cardiovascular disease and increased mortality in older 
adults {{959 DeFronzo,R.A. 1991;1008 Wong,N.D. 1991; 1000 Weijenberg,M.P. 
1996; 1001 Corti,M.C. 1997;  }}. As with obesity, elevated cholesterol levels are not 
always associated with elevated all-cause mortality (3), and there is even evidence of 
the contrary where there is an increased all-cause mortality rate with lower 
cholesterol levels , the latter being associated with concomitant disease (e.g. cancer) 
(4-7). As in obesity, however, lower cholesterol levels may be indicative of concealed 
diseases such as cancer.  In addition, individuals surviving longer with elevated 
cholesterol levels may be less susceptible to complications of dyslipidemia, while 
those susceptible are likely to have died before reaching the age of 75 (3).  Despite 
this, current recommendations are that lipid lowering treatment remains favourable in 
patients aged 65 and older (8) 
 
We aim to review the current literature relating to voluntary weight loss and other 
approaches for cholesterol management in the elderly and to determine if such a 
clinical management decision is beneficial in this population group. 
 
 
Lifestyle modification  
 
There have been a number of interventions assessing the benefits of changes in diet 
and exercise in the elderly. Positive outcomes of diet and exercise have resulted in 
improvement in blood pressure (9), inflammation (10), insulin resistance (11) quality 
of life (12,13), osteoarthritis (14).  Few of them, however, actually assess the benefits 
of weight loss on cholesterol lowering. These are summarised in Table 1. The first 
study to assess the effects of lifestyle modification on CVD risk was carried out by 
Villareal and colleagues (15). They carried out a 6 month randomised controlled trial 
where subjects were assigned to either 26 weeks of treatment with a low-calorie diet 
and exercise training or no treatment. The treatment approach resulted in significant 
weight loss and improvements in triacylglycerols in the intervention group compared 
to both baseline values and the control group (15). 
 
Two recently published interventions compared the use of exercise only compared to 
exercise and calorie restriction in older obese individuals with impaired glucose 
tolerance (16) and metabolic syndrome (17) over a period of 12 weeks. Both papers 
reported significant weight loss in both the control and treatment groups although it 
was greater in the exercise plus diet group. Total cholesterol, triacylglycerols and 
LDL cholesterol were significantly reduced in both the treatment and control groups. 
They suggested that the improvements in circulating lipids were likely due to 
exercise-related improvement in free fatty acid (FFA) -induced insulin resistance 
linked to increased intracellular FFA utilization. In the patients with metabolic 
syndrome, those in the exercise and calorie restriction group did achieve greater 
weight loss, but without greater improvement in biochemical markers of CVD. Some 
evidence suggests that older individuals lose more lean body mass as opposed to fat 
mass in response to energy restriction when compared to younger adults (2) . 
Interestingly, in the patients with metabolic syndrome, although lean body mass was 
mostly preserved, there was a trend for a greater loss of muscle mass in the calorie-
restricted group (17).  This evidence suggests that caution needs to be exercised 
when prescribing an energy-restricted diet in the elderly.  
 
In another study {{912 Kallings,L.V. 2009; }}, a group of obese 68 year olds were 
randomised to either physical activity on prescription or a minimal intervention for 6 
months. These results are not presented in Table 1 as the data were reported in 
absolute change and confidence intervals (CI). Weight loss was significant in the 
intervention group (mean (standard deviation): -1.8 (0.05); 95% CI: -2.8 to -0.8). 
Individualised exercise on prescription also improved body composition (percentage 
body fat: -1.2 (0.4) with 95 % CI: -2.0 to -0.5; fat mass: -1.7 (0.4) with 95% CI: -2.5 to 
-0.9; waist circumference: -2.3 (0.6) with 95 % CI: -3.5 to -1.1). Total cholesterol 
decreased significantly more in the intervention compared to the control group after 6 
months (P = 0.042).  
 
Limitations in terms of studies assessing weight loss in the elderly obese, are that 
aging is associated with a loss of bone and lean mass, water (18) and an increase in 
abdominal obesity (19). The current definitions of body mass index are not 
necessarily suitable for the definition of obesity in the elderly (20) and future studies 
may require to define obesity in terms of body fat or abdominal adiposity. One 
recently published systematic review (21) did not report a significant improvement in 
cholesterol in response to a moderate but significant weight loss in older (≥60 years) 
obese people. These results may have been influenced by the lack of a proper 
definition for obesity in the elderly as well as the fact that the review included papers 
with mean ages from 60-69 which may have included younger adults and blurred the 
outcomes for those 65 years of age or older (21). 
 Table 1: Weight and lipid changes for lifestyle intervention studies. 
 
Author (year) N Age Intervention Duration 
(weeks) 
Weight 
(Kg) 
HDL (mmol/L) Triacylglycerols 
(mmol/L) 
LDL (mmol/L) Total cholesterol 
(mmol/l) 
     Baseline End Baseline End Baseline End Baseline End Baseline End 
Villareal et al 
(2006){{987 
Villareal,D.T. 
2006; }} 
10 
 
 
17 
69 
(5) 
No TX 
 
 
CR + EX 
26  103 (20) 
 
 
100(14) 
103.7 
(-) 
 
91.8  
(-)*1 
1.11 
(0.13) 
 
1.24 
(0.23) 
1.09 
(0.13) 
 
1.21 
(0.23) 
1.50 
(0.44) 
 
2.03(0.98) 
1.50 
(0.68) 
 
1.53 
(0.62)*1 
3.08 
(0.54) 
 
2.85 
(0.85) 
3.19 
(0.70) 
 
2.69 
(0.65) 
- - 
Yassine et al 
(2009){{991 
Yassine,H.N. 
2009; }} 
12 
 
 
12 
65.5 
(5) 
EX 
 
 
CR + EX 
12  99.7 
(15.7) 
 
94.9 
(16.5) 
95.9 
(14.6)* 
 
88.0 
(14.5)*1 
0.96 
(0.21) 
 
0.89 
(0.15) 
0.97 
(0.20) 
 
0.87 
(0.20) 
1.91 
(0.71) 
 
1.93 
(0.59) 
1.52 
(0.42)* 
 
1.32 
(0.54)* 
2.82 
(0.74) 
 
3.06 
(0.45) 
2.63 
(0.60)* 
 
2.70 
(0.49)* 
4.68 
(0.96) 
 
4.69 
(0.62) 
4.19 
(0.84)* 
 
4.07 
(0.72)* 
Solomon et 
al 
(2009){{990 
Solomon,T.P. 
2009; }} 
8 
 
 
8 
66 
(1) 
EX 
 
 
CR + EX 
12  96.0 
(6.1) 
 
88.4 
(4.6) 
92.8 
(6.0)* 
 
81.7 
(4.4)*1 
-  -  2.22 
(0.51) 
 
2.37 
(0.29) 
1.90 
(0.29)* 
 
1.93 
(0.31)* 
- -  5.42 
(0.25) 
 
5.77 
(0.82) 
5.26 
(0.27)* 
 
5.04 
(0.27)*1 
 
All data are presented as mean and standard deviation unless described otherwise. Significant difference from corresponding baseline value: * 
P<0.05. Significant difference in change between the two groups: 1 P<0.05. Abbreviations: TX – treatment; CR – calorie restricted; EX - 
exercise
 
 
Medication 
Similarly, with diet therapy, there is limited literature relating to the use of medication 
for weight loss and for cholesterol lowering in the elderly.  
 
Until very recently, there were two drugs available for the treatment of obesity in the 
UK. Unfortunately, following the findings from the Sibutramine  Cardiovascular 
Outcome Trial (SCOUT) where sibutramine was associated with increased 
complications of cardiovascular disease, this drug has been removed from the 
market by the European Medicines Agency (EMEA). This leaves us with only one 
available drug, Xenical, in the management of obesity. No trials assessing the use of 
Xenical in the elderly have been conducted to date.  One study, however, suggested 
that Xenical could be used safely in an older population, and that in combination with 
a reduced-calorie diet, weight loss and improvements in cardiovascular markers were 
observed (22) 
 
A number of studies have assessed the use of statins and fibrates in the 
management of dyslipidemia (23-29). Few of these, however, directly assessed the 
use in elderly subjects (23,25,30-33), although some did present subset analyses 
(24,26,34-36,36,37). The limited amount of evidence available does suggest that the 
first-line of drug therapy should be statins for the general population (38). There have 
been significant reductions in the incidence of coronary events and associated 
mortality observed in response to statin treatment in the elderly, but that long-term 
compliance is an important issue which needs to be addressed (30,31). In addition, 
there is some evidence of exacerbated joint pain and general muscular ache 
associated with statin (39) This impacts adversely on quality of life and it is the main 
reason for stopping statin treatment.  
 
Surgery 
 
There have been two observational restrospective studies carried out in the last few 
years (40,41). In a cohort study, 216 elderly (60 years and over) patients were 
selected from the database of the Gruppo Italiano Lap-Band after having undergone 
laparoscopic adjustable gastric banding and analysed according to co-morbidities, 
per-operative complications and weight loss (40). The results suggested that despite 
a lower weight loss than <60 year old group, significant improvement in dyslipidemia 
was observed (Table 2).   
 
In a prospective review of individuals 60 years of age and older who underwent 
LAGB, weight loss, complications, comorbidities, medication and quality of life were 
assessed. The results suggested that following LAGB, patients displayed a 
significant weight loss, improvement in quality of life and reduction in medication as 
well improvements in comordities such as dyslipidemia (Table 2). Nevertheless, the 
authors do state that, despite these benefits, in older patients whose comorbidities 
are unlikely to improve with weight loss and increase and where there is an increase 
in peri-operative complications, surgery remains contra-indicated (42).  More 
recently, a restrospective cohort study of high-risk patients investigating survival 
rates and changes in weight-related comorbidities between individuals who 
underwent surgery to a similar cohort of patients who did not undergo surgery was 
carried out (41). The results suggested that bariatric surgery increased survival rates 
in these high risk individuals and a decrease in weight related comorbidities 
compared to those who did not undergo surgery.  An-age related increase in peri-
operative morbidity and mortality has, however, been observed in particular for 
gastric bypass compared to laparoscopic gastric band (LAGB) (43). This clearly 
warrants the need for more clinical trials to evaluate the use of bariatric surgery in the 
elderly. 
 
 
Table 2: Studies investigating the use of bariatric surgery in the elderly. 
 
Author 
(year) 
Intervention Age 
(years) 
Follow 
up 
Mean 
BMI at 
baseline 
Mean 
BMI 
at 
follow 
up 
Presenting 
with 
dyslipidemia 
at baseline 
(N) 
Improved 
dyslipidemia 
at follow up 
(N) 
Taylor et al 
(2006){{985 
Taylor,C.J. 
2006; }} 
Laparoscopic 
banding 
≥ 60 Mean 
27 
months 
42.2 
(range 
33-54) 
- 21/35 17/21 (80%) 
Busetto et 
al 
(2008){{982 
Busetto,L. 
2008; }} 
Laparoscopic 
banding 
≥ 60 5 year 
post-
op  
44.2 
(SD 7.6) 
35.9 
(SD 
7.6) 
26/216 
(11.9%) 
10/26 
(38.5%) 
 
Conclusion 
 
There is currently a clear paucity of information about the use of diet, medication and 
surgery for weight loss and cholesterol lowering in the elderly. It also remains unclear 
what the overall risks and benefits of weight loss and cholesterol lowering are. 
 
Diet, exercise, statin therapy as well as laparoscopic gastric banding appear to be 
effective options for cholesterol lowering in this population group. However, despite 
the association of increased CVD risk with increased cholesterol, there remains 
some evidence that elevated cholesterol levels in the elderly could have some 
benefits. Due to this controversy, and the lack of substantial evidence for clear 
guidelines, we suggest that additional research into the risks and benefits of weight 
loss and cholesterol lowering in the elderly is needed. In the meantime, weight and 
cholesterol management in the elderly requires a thorough clinical evaluation and a 
case specific approach assessing the individual’s functional age, weight history, 
medication and comorbidities.  Where weight loss and cholesterol lowering is 
recommended, an exercise regimen should be the first line of treatment followed by 
the use of statins as second line therapy where exercise is either not possible or 
unsuccessful. There also remains an important scope for the use of gastric banding 
in those where exercise and drugs are not an option.   
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